- Home
- QNCX vs ACCS Comparison
QNCX vs ACCS Comparison
Compare QNCX & ACCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNCX
- ACCS
- Stock Information
- Founded
- QNCX 2012
- ACCS 1988
- Country
- QNCX United States
- ACCS United States
- Employees
- QNCX N/A
- ACCS N/A
- Industry
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- ACCS Publishing
- Sector
- QNCX Health Care
- ACCS Consumer Discretionary
- Exchange
- QNCX Nasdaq
- ACCS Nasdaq
- Market Cap
- QNCX 47.7M
- ACCS 46.0M
- IPO Year
- QNCX 2019
- ACCS N/A
- Fundamental
- Price
- QNCX $1.31
- ACCS $12.05
- Analyst Decision
- QNCX Strong Buy
- ACCS Strong Buy
- Analyst Count
- QNCX 5
- ACCS 1
- Target Price
- QNCX $8.00
- ACCS $15.00
- AVG Volume (30 Days)
- QNCX 302.6K
- ACCS 8.7K
- Earning Date
- QNCX 08-12-2025
- ACCS 08-07-2025
- Dividend Yield
- QNCX N/A
- ACCS N/A
- EPS Growth
- QNCX N/A
- ACCS N/A
- EPS
- QNCX N/A
- ACCS N/A
- Revenue
- QNCX N/A
- ACCS $22,961,000.00
- Revenue This Year
- QNCX N/A
- ACCS $7.67
- Revenue Next Year
- QNCX N/A
- ACCS N/A
- P/E Ratio
- QNCX N/A
- ACCS N/A
- Revenue Growth
- QNCX N/A
- ACCS 6.92
- 52 Week Low
- QNCX $0.51
- ACCS $7.61
- 52 Week High
- QNCX $2.45
- ACCS $13.35
- Technical
- Relative Strength Index (RSI)
- QNCX 64.64
- ACCS N/A
- Support Level
- QNCX $1.29
- ACCS N/A
- Resistance Level
- QNCX $1.45
- ACCS N/A
- Average True Range (ATR)
- QNCX 0.09
- ACCS 0.00
- MACD
- QNCX 0.03
- ACCS 0.00
- Stochastic Oscillator
- QNCX 76.74
- ACCS 0.00
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
About ACCS ACCESS Newswire Inc. Common Stock
ACCESS Newswire Inc is a Public Relations (PR) and Investor Relations (IR) solutions provider. The group focuses on innovation, customer service, and value-driven offerings, ACCESS Newswire empowers brands.